Half of the patients who received an experimental vaccine for pancreas cancer being developed by Roche and BioNTech following ...

David Roche of Quantum Strategy discusses his optimism for the new German government following their recent elections. He ...

According to Roche subsidiary Genentech, which announced the label expansion on Monday, TNKase is the first new drug for ...

Roche's Q4 results and innovative advancements make it a strong pick. Its late-stage pipeline supports our belief that there ...

Illumina navigates competition and geopolitical risks with improved margins and strong cash flow. Read my analysis of ILMN ...

Posay, the dermatologist-recommended leader in skincare, is thrilled to announce its partnership with the BNP Paribas Open as ...

Submission is supported by positive results from the Phase III REGENCY trial, which demonstrated that nearly half of patients ...

The value that laboratories contribute to clinical decision-making is critical to the future of health care and enables ...

Genentech has had the lone medicine on the market for the acute treatment of stroke. | Over nearly the last three decades, ...

Former Walton Family Enterprises CEO expands BanyanGlobal’s family office capabilities as the preeminent advisor to owners of ...

Roche’s Genentech unit has received approval from the US Food and Drug Administration (FDA) for TNKase (tenecteplase) in ...

Roche introduces Sequencing by Expansion (SBX) technology in a webinar just a few days before the AGBT meeting takes place in ...